Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Core Scientific (CORZ) Equity Average (2021 - 2025)

Core Scientific's Equity Average history spans 5 years, with the latest figure at -$1.2 billion for Q3 2025.

  • For Q3 2025, Equity Average fell 15.55% year-over-year to -$1.2 billion; the TTM value through Sep 2025 reached -$1.2 billion, down 15.55%, while the annual FY2024 figure was -$708.6 million, 40.83% down from the prior year.
  • Equity Average for Q3 2025 was -$1.2 billion at Core Scientific, down from -$750.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $1.2 billion in Q1 2022 and bottomed at -$1.2 billion in Q3 2025.
  • The 5-year median for Equity Average is -$403.4 million (2023), against an average of -$225.4 million.
  • The largest annual shift saw Equity Average soared 1224.13% in 2022 before it plummeted 265.72% in 2023.
  • A 5-year view of Equity Average shows it stood at $645.1 million in 2021, then crashed by 126.07% to -$168.2 million in 2022, then tumbled by 202.0% to -$507.8 million in 2023, then plummeted by 62.14% to -$823.4 million in 2024, then crashed by 40.87% to -$1.2 billion in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Equity Average are -$1.2 billion (Q3 2025), -$750.4 million (Q2 2025), and -$564.5 million (Q1 2025).